CA2922507C - Single-layer oral dose of neuro-attenuating ketamine - Google Patents

Single-layer oral dose of neuro-attenuating ketamine Download PDF

Info

Publication number
CA2922507C
CA2922507C CA2922507A CA2922507A CA2922507C CA 2922507 C CA2922507 C CA 2922507C CA 2922507 A CA2922507 A CA 2922507A CA 2922507 A CA2922507 A CA 2922507A CA 2922507 C CA2922507 C CA 2922507C
Authority
CA
Canada
Prior art keywords
ketamine
naket
tablet composition
release period
neuro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2922507A
Other languages
English (en)
French (fr)
Other versions
CA2922507A1 (en
Inventor
Alex Nivorozhkin
Nelson Landrau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorsa Therapeutics Inc
Original Assignee
Amorsa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorsa Therapeutics Inc filed Critical Amorsa Therapeutics Inc
Publication of CA2922507A1 publication Critical patent/CA2922507A1/en
Application granted granted Critical
Publication of CA2922507C publication Critical patent/CA2922507C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2922507A 2013-08-26 2014-08-26 Single-layer oral dose of neuro-attenuating ketamine Active CA2922507C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361869884P 2013-08-26 2013-08-26
US61/869,884 2013-08-26
US201462015513P 2014-06-22 2014-06-22
US62/015,513 2014-06-22
PCT/US2014/052786 WO2015031410A1 (en) 2013-08-26 2014-08-26 Single-layer oral dose of neuro-attenuating ketamine

Publications (2)

Publication Number Publication Date
CA2922507A1 CA2922507A1 (en) 2015-03-05
CA2922507C true CA2922507C (en) 2022-07-05

Family

ID=52587281

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2922507A Active CA2922507C (en) 2013-08-26 2014-08-26 Single-layer oral dose of neuro-attenuating ketamine

Country Status (5)

Country Link
US (4) US9913803B2 (enExample)
EP (2) EP3960162A1 (enExample)
JP (2) JP2016531913A (enExample)
CA (1) CA2922507C (enExample)
WO (1) WO2015031410A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
US9913803B2 (en) 2013-08-26 2018-03-13 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
EP3272338B1 (en) 2014-04-17 2020-09-09 Develco Pharma Schweiz AG Oral dosage form of ketamine
EP3193853A1 (en) 2014-09-15 2017-07-26 Janssen Pharmaceutica NV VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
KR102604397B1 (ko) 2014-11-04 2023-11-21 아카디아 파마슈티칼스 인코포레이티드 신경 감쇠 케타민 및 노르케타민 화합물, 이의 유도체, 및 방법
CA2970065A1 (en) 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
MX2019012285A (es) * 2017-04-13 2020-11-06 Ovid Therapeutics Inc Metodos de tratamiento de encefalopatias del desarrollo.
EP3641742B1 (en) * 2017-06-23 2026-03-25 Ketabon GmbH Hydroxynorketamine for the use in the treatment of depression
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
MX2020003546A (es) 2017-10-10 2020-08-03 Douglas Pharmaceuticals Ltd Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
SG11202005896WA (en) 2017-12-22 2020-07-29 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
CA3103440A1 (en) 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Method of treating major depressive disorder
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020075134A1 (en) 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
EP3934632A4 (en) 2019-03-05 2022-11-23 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
KR20220002905A (ko) * 2019-03-25 2022-01-07 더글라스 파머수티클스 리미티드 서방형 약학 제제
US12589083B2 (en) 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
JP2023543211A (ja) * 2020-09-24 2023-10-13 ダグラス ファーマシューティカルズ エルティーディー． 徐放性医薬製剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6216413A (ja) * 1985-07-12 1987-01-24 Teijin Ltd キチン類誘導体を用いた徐放性医薬品組成物
IT1191674B (it) * 1986-03-07 1988-03-23 Eurand Spa Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6492488B1 (en) * 1998-08-02 2002-12-10 Pmd Holdings Corp. Controlled release polyacrylic acid granules and a process for preparing the same
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
US20020160043A1 (en) 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US7157103B2 (en) * 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US6855735B2 (en) 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
WO2003103603A2 (en) * 2002-06-10 2003-12-18 Wyeth Novel formate salt of o-desmethyl-venlafaxine
US20080027119A1 (en) * 2002-07-31 2008-01-31 Lippa Arnold S Methods and compositions employing bicifadine for the treatment of acute pain, chronic pain, and symptoms of neuropathic disorders
WO2006053012A2 (en) * 2004-11-10 2006-05-18 Trinity Laboratories, Inc. Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria
WO2008118785A2 (en) * 2007-03-23 2008-10-02 Tikvah Therapeutics Methods for treating depression using immediate-impact treatments and d-cycloserine
EP2139848A1 (en) 2007-04-26 2010-01-06 Auspex Pharmaceuticals, Inc. Deuterium labelled ketamine
WO2009131794A1 (en) * 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
WO2013003669A2 (en) * 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
JP2015512418A (ja) * 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
US9913803B2 (en) 2013-08-26 2018-03-13 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
WO2015040270A1 (en) 2013-09-23 2015-03-26 Convion Oy A recirculation arrangement and method for a high temperature cell system

Also Published As

Publication number Publication date
EP3035918B1 (en) 2021-06-30
US9913803B2 (en) 2018-03-13
EP3035918A4 (en) 2017-03-29
US20160199304A1 (en) 2016-07-14
USRE50805E1 (en) 2026-02-24
CA2922507A1 (en) 2015-03-05
JP2020079273A (ja) 2020-05-28
US20180153813A1 (en) 2018-06-07
JP2016531913A (ja) 2016-10-13
EP3960162A1 (en) 2022-03-02
US10653629B2 (en) 2020-05-19
US11554100B2 (en) 2023-01-17
EP3035918A1 (en) 2016-06-29
US20200261370A1 (en) 2020-08-20
WO2015031410A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
USRE50805E1 (en) Single-layer oral dose of neuro-attenuating ketamine
US10300141B2 (en) Tamper resistant dosage form comprising inorganic salt
AU657027B2 (en) Controlled release oxycodone compositions
US10064945B2 (en) Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2966737A1 (en) Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
SK284620B6 (sk) Tableta obsahujúca ako účinnú zložku terapeuticky účinné množstvo hydrobromidu galantamínu a spôsob jej prípravy
MX2015002633A (es) Composicion medica oralmente administrada.
EP2606879A1 (en) Multiple unit pellet tablet formulation comprising an opioid
KR20160018702A (ko) 변형 방출 제제
EP3139906B1 (en) A slow-release pharmaceutical formulation
KR20180016651A (ko) 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손
US20160317662A1 (en) Stable oral pharmaceutical composition
US20180028472A1 (en) Tamper-resistant dosage form comprising a polyethylene glycol graft copolymer
KR101515222B1 (ko) 티아넵틴 나트륨 함유 제어방출성 경구용 단층 제제 및 이의 제조방법
HK1184384B (en) Tamper resistant dosage form comprising inorganic salt
HK1184384A (en) Tamper resistant dosage form comprising inorganic salt

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190822

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240816

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240816

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240816

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250822

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250822